Leo Mascarenhas

9.7k total citations · 1 hit paper
149 papers, 3.1k citations indexed

About

Leo Mascarenhas is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Surgery. According to data from OpenAlex, Leo Mascarenhas has authored 149 papers receiving a total of 3.1k indexed citations (citations by other indexed papers that have themselves been cited), including 79 papers in Pulmonary and Respiratory Medicine, 43 papers in Oncology and 36 papers in Surgery. Recurrent topics in Leo Mascarenhas's work include Sarcoma Diagnosis and Treatment (50 papers), Lung Cancer Treatments and Mutations (20 papers) and Childhood Cancer Survivors' Quality of Life (19 papers). Leo Mascarenhas is often cited by papers focused on Sarcoma Diagnosis and Treatment (50 papers), Lung Cancer Treatments and Mutations (20 papers) and Childhood Cancer Survivors' Quality of Life (19 papers). Leo Mascarenhas collaborates with scholars based in United States, France and Germany. Leo Mascarenhas's co-authors include Rajkumar Venkatramani, Douglas S. Hawkins, Marcio H. Malogolowkin, Theodore W. Laetsch, Steven G. DuBois, Noah Federman, Catherine M. Albert, Scott Cruickshank, Wendy Landier and Alberto S. Pappo and has published in prestigious journals such as Journal of Clinical Oncology, Blood and PLoS ONE.

In The Last Decade

Leo Mascarenhas

144 papers receiving 3.0k citations

Hit Papers

Larotrectinib for paediat... 2018 2026 2020 2023 2018 100 200 300
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Larotrectinib for paediatric solid tumours harbouring NTRK gene fusions: phase 1 results from a multicentre, open-label, phase 1/2 study
    2018 378 citations Theodore W. Laetsch, Steven G. DuBois et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Leo Mascarenhas United States 28 1.3k 966 792 551 512 149 3.1k
Hélène Pacquement France 36 1.4k 1.0× 1.1k 1.1× 748 0.9× 899 1.6× 1.1k 2.1× 108 4.1k
Fariba Navid United States 31 1.3k 1.0× 896 0.9× 686 0.9× 222 0.4× 351 0.7× 104 2.8k
Iyad Sultan Jordan 26 1.3k 0.9× 941 1.0× 666 0.8× 195 0.4× 619 1.2× 126 3.1k
Cynthia E. Herzog United States 32 1.1k 0.9× 1.0k 1.0× 617 0.8× 209 0.4× 302 0.6× 91 2.7k
Nathalie Gaspar France 27 867 0.7× 583 0.6× 624 0.8× 301 0.5× 247 0.5× 114 2.1k
Jean B. Belasco United States 24 1.1k 0.9× 535 0.6× 511 0.6× 337 0.6× 290 0.6× 62 2.9k
Nicolas Sirvent France 28 962 0.7× 632 0.7× 510 0.6× 653 1.2× 400 0.8× 115 2.7k
Bruce Morland United Kingdom 30 581 0.4× 963 1.0× 639 0.8× 315 0.6× 239 0.5× 95 2.8k
Perrine Marec‐Bérard France 25 1.6k 1.2× 703 0.7× 415 0.5× 238 0.4× 379 0.7× 138 2.7k
Marcio H. Malogolowkin United States 37 1.1k 0.9× 1.0k 1.0× 1.8k 2.3× 753 1.4× 285 0.6× 124 4.2k

Countries citing papers authored by Leo Mascarenhas

Since Specialization
Citations

This map shows the geographic impact of Leo Mascarenhas's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Leo Mascarenhas with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Leo Mascarenhas more than expected).

Fields of papers citing papers by Leo Mascarenhas

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Leo Mascarenhas. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Leo Mascarenhas. The network helps show where Leo Mascarenhas may publish in the future.

Co-authorship network of co-authors of Leo Mascarenhas

This figure shows the co-authorship network connecting the top 25 collaborators of Leo Mascarenhas. A scholar is included among the top collaborators of Leo Mascarenhas based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Leo Mascarenhas. Leo Mascarenhas is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Indelicato, Daniel J., Safia K. Ahmed, Mark Krailo, et al.. (2025). Preoperative Radiotherapy in Patients With Localized Ewing Sarcoma Enrolled on AEWS1031: A Report From the Children's Oncology Group. Pediatric Blood & Cancer. 72(8). e31820–e31820.
2.
Shulman, David S., Kelly Klega, Nan Chen, et al.. (2024). Prospective evaluation of pre-treatment ctDNA burden in localized osteosarcoma to identify patients with inferior outcomes: A report from the LEOPARD study.. Journal of Clinical Oncology. 42(16_suppl). 11510–11510. 1 indexed citations
3.
Grohar, Patrick J., Karla V. Ballman, Leo Mascarenhas, et al.. (2024). SARC037: Phase II results of trabectedin given as a 1-hour (h) infusion in combination with low dose irinotecan in patients (pts) with relapsed/refractory Ewing sarcoma (ES).. Journal of Clinical Oncology. 42(16_suppl). 11508–11508. 5 indexed citations
4.
Malvar, Jemily, Yueh‐Yun Chi, Eugene S. Kim, et al.. (2023). Survival outcomes and surgical morbidity based on surgical approach to pulmonary metastasectomy in pediatric, adolescent and young adult patients with osteosarcoma. Cancer Medicine. 12(20). 20231–20241. 6 indexed citations
5.
Allen‐Rhoades, Wendy, Leo Mascarenhas, Wei Xue, et al.. (2022). ARST2031: A study to compare early use of vinorelbine and maintenance therapy for patients with high risk rhabdomyosarcoma.. Journal of Clinical Oncology. 40(16_suppl). TPS11591–TPS11591. 5 indexed citations
6.
Crane, Jacquelyn, Wei Xue, Amira Qumseya, et al.. (2022). Clinical group and modified TNM stage for rhabdomyosarcoma: A review from the Children's Oncology Group. Pediatric Blood & Cancer. 69(6). e29644–e29644. 24 indexed citations
7.
Mascarenhas, Leo, Chitose Ogawa, Theodore W. Laetsch, et al.. (2021). Phase 1 trial of olaratumab monotherapy and in combination with chemotherapy in pediatric patients with relapsed/refractory solid and central nervous system tumors. Cancer Medicine. 10(3). 843–856. 2 indexed citations
8.
Warren, Mikako, Jemily Malvar, Joseph M. Miller, et al.. (2021). Kaposiform hemangioendothelioma of the bone in children and adolescents. Pediatric Blood & Cancer. 69(1). e29392–e29392. 7 indexed citations
9.
McDermott, Ray, Cornelis M. van Tilburg, Anna F. Farago, et al.. (2020). 1955P Survival benefits of larotrectinib in an integrated dataset of patients with TRK fusion cancer. Annals of Oncology. 31. S1101–S1102. 13 indexed citations
10.
Mascarenhas, Leo, Yueh-Yun Chi, Pooja Hingorani, et al.. (2019). Randomized Phase II Trial of Bevacizumab or Temsirolimus in Combination With Chemotherapy for First Relapse Rhabdomyosarcoma: A Report From the Children’s Oncology Group. Journal of Clinical Oncology. 37(31). 2866–2874. 75 indexed citations
11.
Davis, Lara E., Vanessa Bolejack, Christopher W. Ryan, et al.. (2019). Randomized Double-Blind Phase II Study of Regorafenib in Patients With Metastatic Osteosarcoma. Journal of Clinical Oncology. 37(16). 1424–1431. 174 indexed citations
12.
Setty, Bhuvana A., et al.. (2017). VIncristine, irinotecan, and temozolomide in children and adolescents with relapsed rhabdomyosarcoma. Pediatric Blood & Cancer. 65(1). 27 indexed citations
13.
Su, Albert, Lawrence K. Low, Xin‐Min Li, et al.. (2014). De Novo Congenital Melanoma. American Journal of Dermatopathology. 36(11). 915–919. 10 indexed citations
14.
Armenian, Saro H., Sarah Gelehrter, Rajkumar Venkatramani, et al.. (2014). Carnitine and Cardiac Dysfunction in Childhood Cancer Survivors Treated with Anthracyclines. Cancer Epidemiology Biomarkers & Prevention. 23(6). 1109–1114. 12 indexed citations
15.
Venkatramani, Rajkumar, James E. Stein, Amit Sapra, et al.. (2014). Effect of neoadjuvant chemotherapy on resectability of stage III and IV hepatoblastoma. British journal of surgery. 102(1). 108–113. 26 indexed citations
16.
Venkatramani, Rajkumar, Marcio H. Malogolowkin, & Leo Mascarenhas. (2013). Treatment of multiply relapsed wilms tumor with vincristine, irinotecan, temozolomide and bevacizumab. Pediatric Blood & Cancer. 61(4). 756–759. 20 indexed citations
17.
Venkatramani, Rajkumar, Kenneth Wong, Arthur J. Olch, et al.. (2013). Correlation of Clinical and Dosimetric Factors With Adverse Pulmonary Outcomes in Children After Lung Irradiation. International Journal of Radiation Oncology*Biology*Physics. 86(5). 942–948. 22 indexed citations
18.
Bhatia, Smita, Wendy Landier, Lindsey Hageman, et al.. (2012). Nonadherence to Oral Mercaptopurine and Risk of Relapse in Hispanic and Non-Hispanic White Children With Acute Lymphoblastic Leukemia: A Report From the Children's Oncology Group. Journal of Clinical Oncology. 30(17). 2094–2101. 243 indexed citations
19.
Mascarenhas, Leo, Mason Bond, & Nita L. Seibel. (2011). Expanded Access Through Cancer Trials Support Unit to Children's Oncology Group Sarcoma Trial AEWS1031 for Adolescents and Young Adults. Journal of Adolescent and Young Adult Oncology. 1(1). 61–63. 3 indexed citations
20.
Mascarenhas, Leo, Elizabeth Lyden, Philip P. Breitfeld, et al.. (2010). Randomized Phase II Window Trial of Two Schedules of Irinotecan With Vincristine in Patients With First Relapse or Progression of Rhabdomyosarcoma: A Report From the Children's Oncology Group. Journal of Clinical Oncology. 28(30). 4658–4663. 80 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Hélène Pacquement Breakdown of academic impact, for papers by Fariba Navid Breakdown of academic impact, for papers by Iyad Sultan Breakdown of academic impact, for papers by Cynthia E. Herzog Breakdown of academic impact, for papers by Nathalie Gaspar Breakdown of academic impact, for papers by Jean B. Belasco Breakdown of academic impact, for papers by Nicolas Sirvent Breakdown of academic impact, for papers by Bruce Morland Breakdown of academic impact, for papers by Perrine Marec‐Bérard Breakdown of academic impact, for papers by Marcio H. Malogolowkin
Rankless by CCL
2026